Glaucoma is one of the leading causes of permanent blindness in the world, affecting more than two million Americans, and more than one hundred million people worldwide. It is a disease of the optic ...

Bausch + Lomb (NYSE:BLCO) highlighted two glaucoma programs during a Wells Fargo-hosted “2026 MedTech Innovation Spotlight” ...

Glaucoma can be an unpredictable disease that responds differently to treatment options from patient to patient. Despite having several treatment and surgical options available, none of these are ...

A review of selective laser trabeculoplasty in glaucoma management, and when it is appropriate to consider as a treatment option. Neil Minkoff, MD: As we move into different types of therapy, laser ...

In a pivotal clinical trial, an excimer laser procedure reduced IOP in patients with glaucoma, according to a press release ...

Medication, laser, and surgery are all methods of treating glaucoma according to Jonathan Eisengart, MD. Jonathan Eisengart, MD, an ophthalmologist at Cleveland Clinic, explained how different ...

ELIOS achieved statistically significant, clinically meaningful IOP lowering, meeting both co-primary endpoints for responder ...

ALISO VIEJO, Calif., December 03, 2025--(BUSINESS WIRE)--ViaLase, Inc., a clinical-stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced that ...

Glaucoma is a group of conditions that affect the functioning of the optic nerve, the nerve bundle that connects the eye to the brain. The most common form of glaucoma involves increased pressure ...

ViaLase, a medical technology startup developing a new femtosecond laser treatment for glaucoma, has closed its series C funding round with $40 million in additional finance. Based in Alisa Viejo, ...

Shares of Bausch + Lomb rose in premarket trading Monday after the company said that data from its glaucoma procedure trials was positive. Shares in New York traded 5% higher ahead of the morning bell ...